175 related articles for article (PubMed ID: 22171072)
1. An eQTL-based method identifies CTTN and ZMAT3 as pemetrexed susceptibility markers.
Wen Y; Gamazon ER; Bleibel WK; Wing C; Mi S; McIlwee BE; Delaney SM; Duan S; Im HK; Dolan ME
Hum Mol Genet; 2012 Apr; 21(7):1470-80. PubMed ID: 22171072
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies.
Wen Y; Gorsic LK; Wheeler HE; Ziliak DM; Huang RS; Dolan ME
Pharmacogenet Genomics; 2011 Aug; 21(8):476-88. PubMed ID: 21642893
[TBL] [Abstract][Full Text] [Related]
3. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Aug; 10(2):931-8. PubMed ID: 24840891
[TBL] [Abstract][Full Text] [Related]
4. Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma.
Røe OD; Szulkin A; Anderssen E; Flatberg A; Sandeck H; Amundsen T; Erlandsen SE; Dobra K; Sundstrøm SH
PLoS One; 2012; 7(8):e40521. PubMed ID: 22905093
[TBL] [Abstract][Full Text] [Related]
5. Pemetrexed in malignant pleural mesothelioma.
Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163
[TBL] [Abstract][Full Text] [Related]
6. Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy.
Hou J; Lambers M; den Hamer B; den Bakker MA; Hoogsteden HC; Grosveld F; Hegmans J; Aerts J; Philipsen S
J Thorac Oncol; 2012 Jan; 7(1):105-14. PubMed ID: 22134068
[TBL] [Abstract][Full Text] [Related]
7. Predictive markers for haematological toxicity of pemetrexed.
Kao SC; Phan VH; Clarke SJ
Curr Drug Targets; 2010 Jan; 11(1):48-57. PubMed ID: 19839928
[TBL] [Abstract][Full Text] [Related]
8. The inverse relationship between reduced folate carrier function and pemetrexed activity in a human colon cancer cell line.
Chattopadhyay S; Zhao R; Krupenko SA; Krupenko N; Goldman ID
Mol Cancer Ther; 2006 Feb; 5(2):438-49. PubMed ID: 16505119
[TBL] [Abstract][Full Text] [Related]
9. Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation.
Dundar Y; Bagust A; Dickson R; Dodd S; Green J; Haycox A; Hill R; McLeod C; Walley T
Health Technol Assess; 2007 Jan; 11(1):1-90. PubMed ID: 17181984
[TBL] [Abstract][Full Text] [Related]
10. Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed.
Cortes-Dericks L; Carboni GL; Schmid RA; Karoubi G
Int J Oncol; 2010 Aug; 37(2):437-44. PubMed ID: 20596671
[TBL] [Abstract][Full Text] [Related]
11. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
Prescrire Int; 2005 Dec; 14(80):212-4. PubMed ID: 16400741
[TBL] [Abstract][Full Text] [Related]
12. A meta-analysis of pemetrexed-based doublet compared with pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer.
Sun CT; Xu X; Sheng W; Wang XW; Wen SL; Han JQ
Bratisl Lek Listy; 2014; 115(4):233-7. PubMed ID: 24797599
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Qi WX; Tang LN; He AN; Shen Z; Yao Y
J Cancer Res Clin Oncol; 2012 May; 138(5):745-51. PubMed ID: 22258853
[TBL] [Abstract][Full Text] [Related]
14. Enhanced apoptosis by pemetrexed and simvastatin in malignant mesothelioma and lung cancer cells by reactive oxygen species-dependent mitochondrial dysfunction and Bim induction.
Hwang KE; Kim YS; Hwang YR; Kwon SJ; Park DS; Cha BK; Kim BR; Yoon KH; Jeong ET; Kim HR
Int J Oncol; 2014 Oct; 45(4):1769-77. PubMed ID: 25096993
[TBL] [Abstract][Full Text] [Related]
15. Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow.
Das JR; Fryar-Tita EB; Green S; Southerland WM; Bowen D
Anticancer Res; 2007; 27(2):825-33. PubMed ID: 17465208
[TBL] [Abstract][Full Text] [Related]
16. The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy.
Nutt JE; Razak AR; O'Toole K; Black F; Quinn AE; Calvert AH; Plummer ER; Lunec J
Br J Cancer; 2010 Feb; 102(3):553-60. PubMed ID: 20051956
[TBL] [Abstract][Full Text] [Related]
17. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
18. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.
Zucali PA; Giovannetti E; Destro A; Mencoboni M; Ceresoli GL; Gianoncelli L; Lorenzi E; De Vincenzo F; Simonelli M; Perrino M; Bruzzone A; Thunnissen E; Tunesi G; Giordano L; Roncalli M; Peters GJ; Santoro A
Clin Cancer Res; 2011 Apr; 17(8):2581-90. PubMed ID: 21262916
[TBL] [Abstract][Full Text] [Related]
19. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.
Niyikiza C; Baker SD; Seitz DE; Walling JM; Nelson K; Rusthoven JJ; Stabler SP; Paoletti P; Calvert AH; Allen RH
Mol Cancer Ther; 2002 May; 1(7):545-52. PubMed ID: 12479273
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer.
Hsu DS; Balakumaran BS; Acharya CR; Vlahovic V; Walters KS; Garman K; Anders C; Riedel RF; Lancaster J; Harpole D; Dressman HK; Nevins JR; Febbo PG; Potti A
J Clin Oncol; 2007 Oct; 25(28):4350-7. PubMed ID: 17906199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
